Are you using Lantus for keeping a check on your diabetes? Are you not risking your life with cancer? Well the Canadian Health Ministry have a few doubts to clear.
The U.S. Food and Drug Administration has asked all companies to show their diabetes drugs don’t increase chances of cardiac trouble. This new guidance document, announced Wednesday, comes on the heels of reports that two commonly prescribed blood sugar-lowering drugs already on the market, Avandia and Actos, increase the risk of heart failure and, in the case of Avandia, increase the risk of heart attack.
Harvard University researchers have found the diabetes drug Avandia can be harmful to heart and can lead to death. The study was led by Dr. Wolfgang Winkelmayer of Brigham and Women’s Hospital in Boston. He and his colleagues reported people aged 65 and older who took Avandia (rosiglitazone) had a 15 percent higher rate of death after an average of one year.
It seems that the Amylin Pharmaceuticals Inc.is paying the hard times. After the news of death over the diabetes drug Byetta spreads, the shares of the company, fell.
Food and Drug Administration (FDA) has announced a “stronger and more prominent warnings” to the diabetic drug named Byetta. Latest news reveals that since October of 2007 more than six incidents of hemorrhagic or necrotizing pancreatitis in patients have been reported to FDA. Of which two patients have already died.
According to the announcement done on 22 of July 2008, by Santarus Inc.(a renowned San Deigo based company), they have signed an agreement with Depomed Inc. to promote Glumetza (a diabetic drug ) in the U.S market.
A prominent medical expert, Cardiologist Steven Nissen of the Cleveland Clinic urged the U.S. Food and Drug Administration to raise its standards for approving diabetes drugs on Tuesday. Nissen said that companies need to prove new drugs don’t increase cardiovascular disease, the leading killer of diabetics. Nissen suggested that, in addition to requiring more pre-approval studies, companies should have large, long-term studies in place when a drug is approved to monitor whether the drug increases the risk of cardiovascular disease. He discussed the issue of diabetes drugs standards as a part of a two-day meeting starting Tuesday.